Galeterone

Results: 13



#Item
1Microsoft WordDOCX

Microsoft WordDOCX

Add to Reading List

Source URL: securities.stanford.edu

Language: English - Date: 2016-08-03 18:48:38
2Award ID: CP130020 Project Title: Androgen Receptor N-Terminus Blocker Program for Prostate Cancer Award Mechanism: Company Relocation

Award ID: CP130020 Project Title: Androgen Receptor N-Terminus Blocker Program for Prostate Cancer Award Mechanism: Company Relocation

Add to Reading List

Source URL: www.cprit.state.tx.us

Language: English - Date: 2015-03-24 12:30:06
3September 10, 2012  Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients DUBLIN, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:

September 10, 2012 Astex Pharmaceuticals Announces Initiation of HSP90 Inhibitor AT13387 Clinical Trial in Prostate Cancer Patients DUBLIN, Calif., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:

Add to Reading List

Source URL: astx.com

Language: English
4Microsoft PowerPointGU Disease Site Schema Flowsheet.pptx

Microsoft PowerPointGU Disease Site Schema Flowsheet.pptx

Add to Reading List

Source URL: www.ucdenver.edu

Language: English - Date: 2015-04-07 12:33:12
5R&D Pipeline (October[removed]Global Development (1) Approval / Labeling Revision #Compounds with

R&D Pipeline (October[removed]Global Development (1) Approval / Labeling Revision #Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.) Code No. Gen

Add to Reading List

Source URL: www.astellas.com

Language: English - Date: 2014-10-30 05:54:55
6NEWS RELEASE  FOR IMMEDIATE RELEASE Tokai Pharmaceuticals to Present at the 34th Annual Cowen Health Care Conference CAMBRIDGE, Mass., February 24, 2014 – Tokai Pharmaceuticals, Inc., a

NEWS RELEASE FOR IMMEDIATE RELEASE Tokai Pharmaceuticals to Present at the 34th Annual Cowen Health Care Conference CAMBRIDGE, Mass., February 24, 2014 – Tokai Pharmaceuticals, Inc., a

Add to Reading List

Source URL: www.tokaipharma.com

Language: English - Date: 2014-02-24 08:43:32
7NEWS RELEASE  FOR IMMEDIATE RELEASE New Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone in Advanced Prostate Cancer to be Presented at 2014 ASCO GU Symposium CAMBRIDGE, Mass., January 9, 2014 – Tokai Pharm

NEWS RELEASE FOR IMMEDIATE RELEASE New Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone in Advanced Prostate Cancer to be Presented at 2014 ASCO GU Symposium CAMBRIDGE, Mass., January 9, 2014 – Tokai Pharm

Add to Reading List

Source URL: www.tokaipharma.com

Language: English - Date: 2014-01-09 09:29:29
8NEWS RELEASE  FOR IMMEDIATE RELEASE Tokai Pharmaceuticals Appoints Karen J. Ferrante, M.D. as Head of R&D and Chief Medical Officer CAMBRIDGE, Mass., April 15, 2014 – Tokai Pharmaceuticals, Inc., a biopharmaceutical

NEWS RELEASE FOR IMMEDIATE RELEASE Tokai Pharmaceuticals Appoints Karen J. Ferrante, M.D. as Head of R&D and Chief Medical Officer CAMBRIDGE, Mass., April 15, 2014 – Tokai Pharmaceuticals, Inc., a biopharmaceutical

Add to Reading List

Source URL: www.tokaipharma.com

Language: English - Date: 2014-04-15 10:19:58
9NEWS RELEASE  FOR IMMEDIATE RELEASE Tokai Pharmaceuticals Appoints John McBride as Chief Operating Officer CAMBRIDGE, Mass., February 11, 2014 – Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on devel

NEWS RELEASE FOR IMMEDIATE RELEASE Tokai Pharmaceuticals Appoints John McBride as Chief Operating Officer CAMBRIDGE, Mass., February 11, 2014 – Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on devel

Add to Reading List

Source URL: www.tokaipharma.com

Language: English - Date: 2014-02-11 08:59:12
10NEWS RELEASE  FOR IMMEDIATE RELEASE Tokai Pharmaceuticals’ Reformulated Galeterone Demonstrates Robust PSA Reductions in Advanced Prostate Cancer Patients Interim Results from ARMOR2 Phase 2 Study Presented at 2014 ASC

NEWS RELEASE FOR IMMEDIATE RELEASE Tokai Pharmaceuticals’ Reformulated Galeterone Demonstrates Robust PSA Reductions in Advanced Prostate Cancer Patients Interim Results from ARMOR2 Phase 2 Study Presented at 2014 ASC

Add to Reading List

Source URL: www.tokaipharma.com

Language: English - Date: 2014-01-29 10:23:05